Bryan Johnson: The Millionaire Trying to Stop Himself From Aging

Bryan Johnson has organized his life around a question most people cannot afford to investigate full-time: how much control can one person exert over growing old? Through Project Blueprint, the technology entrepreneur has made meals, sleep, exercise and medical measurements part of an unusually public experiment. He is its subject, financier and most recognizable salesman.

His ambition now reaches 2039, the year by which he says he wants to achieve immortality. That is Johnson's stated goal, not a verified scientific timetable. Nothing in the evidence reviewed for this profile establishes that he has stopped aging, reversed aging throughout his body or secured a longer lifespan. Johnson: his 2039 ambition

THE FORTUNE THAT BOUGHT HIM TIME

Johnson built Braintree, a payments company founded in 2007, into the business that financed his reinvention. Braintree acquired Venmo, then became part of PayPal when eBay completed its approximately $800 million cash acquisition in December 2013. The price covered the company, including Venmo. It was not a personal $800 million payment to Johnson. Chicago Booth: Johnson's business career eBay: completed Braintree acquisition (2013)

That distinction also matters when searching for Bryan Johnson's net worth. A company sale price is not an audited statement of its founder's present wealth. This profile does not assign him a current net-worth figure because the sources reviewed do not establish one. Investments, ownership stakes, taxes and expenditure all separate a headline transaction from personal assets.

His later ventures extended the same interest in changing what technology can do. Chicago Booth documented $100 million commitments to OS Fund and Kernel; Kernel says Johnson founded it in 2016 to develop brain-measurement technology. These are investments and companies he built, not additional verified exits equivalent to the Braintree sale. Chicago Booth: Johnson's business career Kernel: company history

WHY BLUEPRINT BECAME PERSONAL

In his own retrospective account, financial success coincided with a decade of depression. He described selling Braintree, leaving his childhood religion and ending a 13-year marriage as part of a profound reset. This is his public account of his mental health and motivation, not an independent clinical assessment. Bryan Johnson: The past 4 years (2018)

Johnson dates his Blueprint undertaking to 2021. His explanation is strikingly personal: the version of himself who overate at night was undermining the person who needed to sleep, work and parent the next day. He began treating decisions about his body as a system to redesign, rather than a contest of willpower at every meal. Johnson: Don't Die and the 2021 project

The result is more than a fitness plan. It is an attempt to move authority from impulse to measurement. That makes him an unusual subject for a lifestyle profile: the luxury he has purchased is not simply leisure, but the staff, equipment and time to structure ordinary life around physiological feedback.

A DAY ARRANGED AROUND THE BODY

The routine below summarizes his published 2026 schedule as reviewed on October 2. It is a self-described snapshot, not independent observation of every day or a prescription for readers. His daily schedule lists a roughly 5 a.m. wake-up, a 6 a.m. workout lasting 60 to 90 minutes and morning body-composition measurements. Johnson: published 2026 protocol, reviewed October 2

Sleep sets the boundaries. In a separate evening-routine account, he says he finishes eating around noon and goes to bed around 8:30 p.m. He describes protecting the evening from screens and stimulation. His claims about unusually high sleep scores refer to tracking metrics, not proof that a particular bedtime extends human life. Johnson: evening routine (2026)

This routine leaves less room for spontaneous late dinners or evenings that run long. But describing him as simply isolated would also be inaccurate. His published schedule includes friends and family, and recreational activities such as hiking, cycling and pickleball. The social question is how life fits around the protocol, not whether a protocol abolishes personal life. Johnson: published 2026 protocol, reviewed October 2

SUPPLEMENTS, MEDICATIONS AND THE MEASUREMENT HABIT

His current disclosure lists creatine, omega-3 and NR or NMN, alongside prescription drugs including metformin, acarbose and thyroid treatment for diagnosed hypothyroidism. These are different categories: nutritional products, drugs used experimentally for longevity, and treatment of an existing condition should not be conflated. The list changes and is not a dosing guide. Johnson: published 2026 protocol, reviewed October 2

Johnson's archived records show why the project attracts attention: blood tests sit alongside body-composition analysis, fitness measures, imaging and detailed tracking of individual organs and bodily functions. Counting measurements does not itself establish their clinical value. A test can produce a number without answering whether an intervention prevents illness or adds years of life. Johnson: archived Blueprint measurements and protocol

His 2026 public measurement framework lists blood draws every three to six months and annual whole-body MRI for people over 40 or with high-risk family histories. This is his published framework, not proof that every personal test follows a fixed interval. Daily measurements and periodic medical investigations should not be described as the same monitoring frequency. Johnson: published 2026 protocol, reviewed October 2

More screening is not automatically better. The American College of Radiology says evidence does not justify recommending whole-body MRI for people without symptoms, risk factors or a relevant family history. Incidental findings can lead to further testing and expense. Johnson's capacity to investigate almost everything is not evidence that everyone should. American College of Radiology: whole-body screening MRI

EXPERIMENTS THAT CHANGED, AND ONES HE STOPPED

In 2023, Johnson stopped young-plasma exchanges, including one involving his son, after reporting no detected benefit. Fortune: Johnson reports no benefit from young plasma (2023)

The FDA's December 2024 warning states that young-donor plasma has no established clinical benefit for aging and is not approved for that purpose. Transfusion carries risks, including allergic reactions and respiratory complications. Research into blood biology does not validate commercial claims that young blood rejuvenates healthy adults. FDA: young-donor plasma warning (2024)

Rapamycin is another discontinued experiment. In his January 2025 account, Johnson said he had stopped it on September 28 after almost five years of experimentation, citing infections, lipid abnormalities, higher glucose and other unwanted effects. These are his reported experiences, not a controlled demonstration that the drug harms or benefits every user. Johnson: stopping rapamycin (2025 account)

He has also described receiving experimental follistatin gene therapy in Honduras in 2023. His own account acknowledges that the intervention was not FDA approved. Claimed changes in muscle or laboratory results after treatment cannot establish that the therapy caused them, especially while numerous other interventions were changing. Johnson: self-reported follistatin experiment (2024)

Other disclosed experiments include joint injections of mesenchymal stromal/stem cells in 2024 and a three-month trial of cerebrolysin, for which he said his team could not measure an effect. The inability to identify a useful biomarker does not establish either safety or efficacy. Johnson: advanced therapies and prescriptions

In February 2026, he published an account of 60 hyperbaric oxygen sessions and claimed improvements in several biomarkers. Hyperbaric treatment has medical applications, but his personal before-and-after report does not demonstrate a longevity benefit in healthy people. Adding an intervention and observing a change is not the same as isolating its effect. Johnson: self-reported hyperbaric oxygen results (2026)

These reversals are part of the story. Blueprint is an evolving experiment rather than one stable formula whose effects have been established. A supplement list, treatment or calorie target quoted from an old interview should not automatically be presented as what he does today.

WHAT HAS IT COST, AND WHAT DOES BLUEPRINT SELL?

Bloomberg reported roughly $2 million in annual spending in 2023. That historical figure is not a verified current budget. Bloomberg Businessweek: historical spending report (2023)

No independently audited 2026 personal-project total was established by the sources reviewed. Research spending, everyday personal expenses, investment in a commercial company and the price charged to customers are different figures. Combining them would create a misleading estimate of what keeping Bryan Johnson alive costs.

Blueprint now sells supplements, protein products, olive oil and skin and hair products, with links to testing and medical services. Its product pages establish what is marketed, not that the products extend life. Johnson has a commercial interest in the attention generated by his experiment, which belongs alongside any discussion of his claimed results. Blueprint: current commercial products

In February 2026, Axios reported an Immortals offer priced at $1 million for access to his elaborate longevity program. An advertised customer price is neither his own annual expenditure nor evidence of clinical effectiveness. The business has expanded from sharing a personal regimen to selling products and access around it. Axios: Immortals program announcement (2026)

WHAT HIS BIOLOGICAL-AGE NUMBERS ACTUALLY SHOW

In May 2025, Johnson publicized a best DunedinPACE result of 0.48 and a three-test average of 0.54. These are self-reported results from a DNA-methylation-based pace-of-aging estimate, not a statement that his chronological age has halved. His language about birthdays becoming less frequent is metaphor, not a change to time. Johnson: self-reported DunedinPACE results (2025)

A biological-age estimate depends on the test, reference population and method. A favorable result can be a research signal without proving that all organs are younger or that death has been postponed. Different clocks need not agree. For the biology behind these measurements, read PRESDA's Anti-Aging: Can We Actually Slow Down Human Aging?, now in SCIENCE. Nature Aging: randomized CALERIE trial analysis (2023)

WHERE INDEPENDENT EVIDENCE IS STRONGEST

The most defensible parts of his project are also the least exotic. WHO guidelines support regular aerobic activity and muscle-strengthening work for health. Such evidence supports exercise, not the claim that Johnson's entire package has been validated or that his exact timetable is necessary. WHO: evidence-based physical activity guidelines

Calorie restriction illustrates the distinction. A randomized CALERIE trial analysis found a slowing on DunedinPACE, but not significant changes on PhenoAge or GrimAge. It did not establish that Johnson's regimen extends life. A promising biological signal is a reason for further research, not a certificate of rejuvenation. Nature Aging: randomized CALERIE trial analysis (2023)

A 2026 GeroScience review describes rapamycin's substantial preclinical promise and the remaining challenges in translating it into human clinical practice. Animal lifespan results, selected human outcomes and long-term safety in healthy users are different questions. Neither enthusiasm nor Johnson's decision to stop settles them. GeroScience: rapamycin evidence review (2026)

2039: AN AMBITION, NOT A DEADLINE SCIENCE HAS ACCEPTED

Johnson describes reaching immortality by 2039 as his objective and points to accelerating technology, including AI, as part of his reasoning. His account also discusses growing models of his biology for testing. Those statements describe his hopes and plans. They do not establish that medicine can deliver indefinite survival on that schedule. Johnson: his 2039 ambition

The compelling human story is already here: a wealthy entrepreneur has made avoiding deterioration the organizing principle of his life. His money buys extraordinary capacity to measure and experiment. It cannot buy the missing years of follow-up, a randomized comparison or certainty. The difference between those things is what makes his project fascinating, and what keeps it from being proof.

Hero image: an AI-generated conceptual illustration approved for this profile. It does not document an actual scan, treatment or laboratory visit. Sources and protocol pages reviewed October 2, 2026.